Occurrence and Clinical Effect of Obinutuzumab Antibodies in Patients with Membranous Nephropathy Treated with Obinutuzumab (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0806; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "In MN, anti-rituximab antibodies have been shown to neutralize the cytotoxic activity of rituximab, thereby increasing the risk of relapse of nephrotic syndrome and reducing remission rates. During follow-up, immunized patients showed a higher risk of disease relapse than non-immunized patients. Conclusion Immunization against obinutuzumab is frequent and associated with reduced drug efficacy."
Clinical • Glomerulonephritis • Immunology • Nephrology • Renal Disease
|
|
Maxime Teisseyre; Vesna Brglez; Barbara Seitz-Polski
|